SCHEMBL3134040

SCHEMBL3134040

COc1cc(C(N)=O)ccc1-c1cc2ccccc2oc1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.64
MAOB P27338 4/20 0.60
KDM4E B2RXH2 7/20 0.58
ALDH1A1 P00352 7/20 0.58
LMNA P02545 5/20 0.58
THRB P10828 1/20 0.56
HPGD P15428 6/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
RXFP1 Q9HBX9 1/20 0.54
MIF P14174 1/20 0.53
GAA P10253 2/20 0.52
GLA P06280 1/20 0.52
NOD2 Q9HC29 1/20 0.52
ACHE P22303 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3130399 0.84 MAPT (0.66) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3127507 0.82 NCOA1 (0.59) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL6686813 0.80 MIF (0.72) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3130403 0.79 KDM4E (0.73) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL4493313 0.78 ALDH1A1 (0.62) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3135512 0.77 IMPDH2 (0.60) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3128145 0.77 ALDH1A1 (0.67) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL28917782 0.77 LMNA (0.61) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3910988 0.76 MAPT (0.60) MAPTMAOBKDM4EALDH1A1LMNA
SCHEMBL3910984 0.76 MAPT (0.60) MAPTMAOBKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021333-B1 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS ETHICAL ONCOLOGY SCIENCE S (IT) 2010-07-14 EP disclosed
US-20090203685-A1 ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) 2009-08-13 US disclosed
EP-2021333-A2 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS - Ethical Oncology Science S.p.A. (IT) 2009-02-11 EP disclosed
WO-2007135565-A2 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203685-A1 ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF MKI67, CCNA1, CCNI MAPT 4821/4885MAOB 2580/4885KDM4E 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.